HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases in Mainland China. Its lead product candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; is in phase III clinical trial to treat type 2 diabetes mellitus; is in phase II clinical trial to treat severe hypertriglyceridemia; is in phase II clinical trial to treat primary sclerosing cholangitis; and is in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804, which is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease and is in preclinical trial. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.